¡NOTICIAS DE ÚLTIMA HORA! Pronto puede haber otro tratamiento para pacientes del IP! La compañía ADMA Biologics, Inc. ha desarrollado una nueva opción de tratamiento, RI-002, para los pacientes que…
You may have seen the Jeffery Modell Foundation's name around town, literally, from their educational posters. I was thrilled to come across one in the Chicago O'Hare International Airport. The…
The FDA told Chiasma Inc. that they needed to conduct another clinical trial to gather more "sufficient data". Despite receiving a complete response letter void of any safety concerns from…
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 needs your help! Via Congress.gov the Open Act stands to accelerate cures and treatments for rare disease and it could quite possible double…
Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders back in September. Vitae Pharmaceuticals, Inc. (“Vitae”) is developing VTP-43742 for…
Michael J. Fox Foundation Announces New Research Initiative for Pharmacodynamic (PD) Biomarker Like many other diseases such as Lyme disease, there is no current, easily measured bio-marker for Parkinson’s. Without…
Post Rare Disease Day 2016 the FDA's Office of Special Medical Programs announced a new program that would work to provide funding to patient advocacy groups and other organizations who were studying…
Here at Patient Worthy, we've written quite a bit about Narcolepsy. However, we can't help but think that taking a step back to answer some basic questions about the disease is…
For those of us with rare diseases, the subject of Marinol and other marijuana-derived substances has certainly come up in conversations with doctors, at least in terms of it's pain…
Anyone with rare and neurological disease can relate: there aren't a ton of treatment options and there are almost never any cures for our conditions. We often times just have to treat…
BREAKING NEWS! There may soon be another treatment for PI patients! The company ADMA Biologics, Inc. has developed a new treatment option, RI-002, for patients who are immune-compromised. It’s currently…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
